Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   94663 News 


«12...4849505152535455565758...10641065»
  • ||||||||||  Rituxan (rituximab) / Roche
    Bridging therapies used in trials testing CAR-T therapies. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4983;    
    Despite this possibility, the reporting of bridging therapy combinations and their subsequent response rates and adverse event rates, is highly variable. Of 11 pivotal clinical trials that led to the approval of a CAR-T cell therapy, none clearly reported bridging therapy data that encompassed all three categories (combinations used, response rates, adverse events).
  • ||||||||||  dexamethasone / Generic mfg.
    Hospitalization risk in multiple myeloma episodes of care. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4507;    
    Identifying patients with a higher likelihood of IP helps practices target patient monitoring programs. To understand why patients with prior treatment had lower IP identifying maintenance following initial treatment and patients receiving 3 or more drugs after failure of prior therapy, are worth exploring further.
  • ||||||||||  Ninlaro (ixazomib) / Takeda, iberdomide (CC-220) / BMS
    All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D. (Hall D1) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4110;    
    P2
    Background: The triplet combination daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomide and dexamethasone (VRd) are to date the standard of care for patients with transplant ineligible (TI) newly diagnosed multiple myeloma (MM)...Iberdomide is a novel oral cereblon E3 ligase modulator (CELMoD) that demonstrated promising activity in MM patients refractory to lenalidomide/pomalidomide... The oral tripletiberdomide, ixazomib and dexamethasone demonstrated a favorable efficacy / safety profile in elderly MM patients at first relapse, including in patients with lenalidomide and daratumumab refractory disease.
  • ||||||||||  Elrexfio (elranatamab-bcmm) / Pfizer
    Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38 (Hall A; Poster Bd #: 212a) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4100;    
    P3
    Numerical differences in TEAEs are largely explained by longer exposure in the Isa-VRd arm. This study will evaluate ELRA monotherapy vs elotuzumab-pomalidomide-dexamethasone (EPd), pomalidomide-bortezomib-dexamethasone (PVd), or carfilzomib-dexamethasone (Kd) in patients with RRMM to determine whether ELRA can provide superior clinical benefit...Key inclusion criteria include age of ?18 years, prior multiple myeloma diagnosis with measurable disease (per IMWG criteria), evidence of progressive disease or failure to achieve a response to last line of multiple myeloma therapy, 1 to 4 prior lines of therapy including an anti
  • ||||||||||  Darzalex (daratumumab) / J&J
    First relapse in patients with multiple myeloma: Outcomes and predictors. (Hall A; Poster Bd #: 195) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4083;    
    These factors should be taken into consideration when designing clinical trials in this patient population. In particular, these factors identify a high-risk group of patients not always identified by baseline characteristics and should be the focus of future trials.
  • ||||||||||  ABBV-383 IV / AbbVie
    Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM). (Hall A; Poster Bd #: 178) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4067;    
    P1/2, P3
    While ER analyses indicated promising efficacy and acceptable safety profiles for 40, 60 mg Q3W, and 60 mg Q4W, they support 60 mg Q4W as the optimal ABBV-383 therapeutic dose due to its predicted better therapeutic benefit/risk profile (high response rates, improved/equivalent ?G3 neutropenia, and lower CRS events) and extended dosing interval. ABBV-383 at 60 mg Q4W will be investigated in the registrational phase 3 trial (NCT06158841) in RRMM.
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS
    Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma. (Hall A; Poster Bd #: 171) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4062;    
    The observed median PFS of 26.9 months was comparable to that seen with chronic lenalidomide maintenance and superior to patients who do not receive lenalidomide maintenance. The improvement in PFS was achieved with a fixed duration rather than continuous therapy and without lenalidomide-associated toxicities such as secondary malignancies, chronic diarrhea, and financial toxicity.
  • ||||||||||  VBI-1901 / VBI Vaccines
    Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas. (Hall A; Poster Bd #: 393b) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3205;    
    P1/2
    400/uL at screening are eligible, as people with a preserved immune system are more likely to respond to immunization with VBI-1901 based on the initial phase study...This hazard ratio corresponds to a difference in the mOS observed previously with VBI-1901 and a historical mOS of 8 months in the SOC group. As of January 31 st 2024 , 12 of 60 patients have been randomized and dosed across 8 US sites.
  • ||||||||||  Prevalence of cannabis related potential medication interactions (PMI) among patients with cancer during treatment. (Hall A; Poster Bd #: 202) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2823;    
    The most common cannabis-related PMIs were with acetaminophen (9.5%), dexamethasone (8%), and ondansetron (6.3%). This is one of the first studies to assess cannabis-related drug interactions in patients receiving cancer treatment, and results indicates a significant proportion of cannabis users are at risk for moderate to major PMIs including with chemotherapy.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Intracranial outcomes with ipilimumab and nivolumab in melanoma brain metastases following progression on anti-PD-1 therapy. (Hall A; Poster Bd #: 339) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_863;    
    Ipi/nivo has limited efficacy in patients with progressive MBM post-PD-1 therapy in the absence of local therapy. These results highlight the unmet clinical need for more effective therapies to address progressive MBM post-PD-1 therapy, an increasingly relevant clinical scenario particularly in light of the growing use of adjuvant and neoadjuvant anti-PD-1.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  The subacromial bursa modulates tendon healing after rotator cuff injury in rats. (Pubmed Central) -  Apr 24, 2024   
    Dexamethasone released from the bursa reduced Il1b expression in injured rat supraspinatus tendon, suggesting that the bursa could be used for drug delivery to reduce inflammation in the healing tendon. Our findings indicate that the subacromial bursa contributes to healing in underlying tissues of the shoulder joint, suggesting that its removal during rotator cuff surgery should be reconsidered.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Review, Journal:  Diagnosis, management and therapeutic options for eosinophilic esophagitis. (Pubmed Central) -  Apr 24, 2024   
    In addition, exploring the coexistence or the previous occurrence of other type 2 conditions may suggest the opportunity to specifically target type 2 inflammation through biologic therapy. The complex EoE pathobiology combining inflammatory and functional features, both at organ and systemic level, requires a multidimensional approach relying on the strict integration of gastroenterologists and allergist-immunologists.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Revisiting dexamethasone use in the pediatric emergency department. (Pubmed Central) -  Apr 24, 2024   
    The complex EoE pathobiology combining inflammatory and functional features, both at organ and systemic level, requires a multidimensional approach relying on the strict integration of gastroenterologists and allergist-immunologists. The findings discussed in this review will enable pediatric emergency medicine providers to use dexamethasone effectively as treatment of common pediatric conditions and minimize the occurrence of side-effects caused by gratuitous corticosteroid use.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Revisiting dexamethasone use in the pediatric emergency department. (Pubmed Central) -  Apr 24, 2024   
    The findings discussed in this review will enable pediatric emergency medicine providers to use dexamethasone effectively as treatment of common pediatric conditions and minimize the occurrence of side-effects caused by gratuitous corticosteroid use. The findings discussed in this review will enable pediatric emergency medicine providers to use dexamethasone effectively as treatment of common pediatric conditions and minimize the occurrence of side-effects caused by gratuitous corticosteroid use.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Taurine activates the AKT-mTOR axis to restore muscle mass and contractile strength in human 3D in vitro models of steroid myopathy. (Pubmed Central) -  Apr 24, 2024   
    By subjecting our bioengineered muscle tissues to dexamethasone treatment, we reproduced the molecular and functional aspects of this disease...Taurine treatment, when administered concurrently with corticosteroids, notably enhanced contractile strength and protein turnover by upregulating the AKT-mTOR axis. Our model not only identifies a promising therapeutic target, but also suggests combinatorial treatment that may benefit individuals undergoing corticosteroid treatment or those diagnosed with adrenal tumors.